Table 6. Comparison of relative cardiotoxicities according to type of anti-cancer treatment and schedules.
| Drug | Schedule | Cardiotoxicity index | Recommended max. dose (mg/m2) |
|---|---|---|---|
| Doxorubicin | Rapid infusion | 1 | 400 |
| Doxorubicin | Weekly | 0.7 | 550 |
| Doxorubicin | 24-h infusion | 0.62 | 550 |
| Doxorubicin | 48-h infusion | 0.57 | 625 |
| Doxorubicin | 96-h infusion | 0.5 | 800–1000 |
| Epirubicin | Rapid infusion | 0.44 | 900 |
| Mitoxantrone | Rapid infusion | 2.5 | 160 |
| Daunorubicin | Rapid infusion | 0.5 | 800 |
| Idarubicin | Rapid infusion | 2.67 | 150 |
| Doxorubicin + dexrazoxane | Rapid infusion | 0.5 | 800–1000 |
| Doxorubicin, 300 mg/m2 + dexrazoxane | Rapid infusion | 0.73 | 500 |